 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
HIV 101: Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis in Patients Taking PIs or NNRTIsFebruary 2004 
Updated January 20, 2004. Adapted from the Centers for Disease Control and Prevention: www.cdc.gov/nchstp/tb/tb_hiv_drugs/Table1.htm and www.cdc.gov/nchstp/tb/tb_hiv_drugs/Table2.htm.  This article was provided by Brown Medical School. It is a part of the publication HEPP Report. |
 |
Email
Print-Friendly
Glossary
PDF
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
